We developed a statistical method, BIOSEA, able to identify molecules that are capable of 12 reproducing a desired cellular phenotype, by scanning a large compound collection based on 13 biological similarity. Our method leverages highly incomplete and noisy compound bioactivity 14 signatures from historical high-throughput screening campaigns. We applied our approach in a 15 phenotypic screening workflow and found novel nanomolar inhibitors of cell division that reproduce 16 the mode of action of reference natural products. In a drug discovery setting, our biological hit 17 expansion protocol revealed new inhibitors of the NKCC1 co-transporter for autism spectrum 18 disorders. Furthermore, we demonstrate BIOSEA's capabilities to predict novel targets for old 19 compounds. We report new activities for the drugs nimedipine, fluspirilene and pimozide applicable 20 for compound repurposing and rationalizing drug side effects. Our results highlight the opportunities 21 of reusing public bioactivity data for prospective drug discovery applications where the target or 22 mode of action is not known. 23
The last two decades have witnessed a dramatic change in our understanding of the interactions 1 between small molecules and biological systems 1 . We are currently experiencing an important shift 2 from reductionism 2 , to a more pragmatic vision of living organisms as complex entities whose study 3 cannot be effectively tackled by treating each part in isolation 3 . In this new framework, phenotypic 4 screening has reemerged as a practical solution to finding novel chemical entities, which provide 5 insights into the underlying cellular processes leading to new opportunities for drug discovery 4 . 6
However, phenotypic screening brings about its own challenges such as the identification of the 7 mechanism of action (MoA) and the effective target or targets responsible for these phenotypes 5 . 8
Target and MoA identification play a fundamental role, paving the way to lead optimization via 9 structural approaches, structure-activity relationships (SAR) rationalization and also by improving 10 awareness about ADME (absorption, distribution, metabolism and excretion), safety liabilities and 11 drug-drug interactions. The chemical biology and genomics fields have stood up to the challenge 12 producing elegant solutions for these problems 6 , such as CRISPR/Cas9 gene editing 7 and chemical 13 proteomics-based techniques 8 that yet, bear inherent limitations such as chemical modification of the 14 compounds, challenging specificity or high costs 8 . In the light of these advances, novel computational 15 efforts are now in order to support phenotypic screening. In this work, we demonstrate how to 16 leverage historical bioassay data as compound biological signatures to facilitate phenotypic 17 deconvolution tasks, such as target identification and phenotypic library design. We report here a 18 novel target and chemical structure-independent screening technique to find new chemical compounds 19 to modulate a desired phenotype in a drug discovery setting. 20
Large amounts of pharmacological and bioactivity data accumulate both in public repositories and in 21 proprietary databases in the pharmaceutical industry. A few approaches have attempted to use 22 historical compound annotation data for target identification. For example, the TarFishDock 9 , 23 TargetHunter 10 , Similarity Ensemble Approach 11,12 , ChemMapper 13 and HitPick 14 methods, rely on 24 either 2D or 3D chemical information of ligands or targets and an established molecular structure similarity metric. These methods have been exploited with success in tasks such as the prediction of 1 targets responsible for drug side effects 15 . However, an important limitation is the fact that these 2 methods depend on the availability of crystal structures for the target, or the structural similarity 3 between the compounds and previously known target ligands which confines their performance to 4 well-explored areas in chemical space. 5
In recent years, it has been demonstrated that the cellular phenotype of compounds can be described, 6 and even predicted, by a compound's biological signature: an array of numbers representing the 7 perturbation caused by a chemical entity of interest measured throughout several cellular and 8 biochemical assays 14 . In this context, compounds sharing a similar biological profile tend to modulate 9 similar targets, without necessarily having similar chemical structure 16 . In the past, we and others 17-22 10
have proposed the use of historical high-throughput screening (HTS) activity data to represent 11 molecules in the biological space. The so-called HTS fingerprints (HTSFP) have proven successful 12 for the identification of new targets for known compounds 22 . Since they are structure-independent, 13 HTSFP enable scaffold-independent linking of drug-like molecules to less frequently explored regions 14 in chemical space such as those of complex natural products 16, 22 . 15 By integrating external pharmacological sources of information and HTS data, we have implemented 16 BIOSEA -Biological Similarity Ensemble Approacha novel statistical classifier that is able to 17 establish new relationships between targets and small molecules on the basis of the mutual 18 information between compound biological signatures. Algorithmically, BIOSEA was inspired by the 19 method developed by Pearson 23 for sequence similarity searches (BLAST) and the Similarity 20
Ensemble Approach (SEA) developed by Keiser et al. 11 to compare chemical structures. 21
In this work, first we report an unprecedented phenotypic screening workflow in which BIOSEA was 22 applied to find compounds that modulate a desired cellular phenotype across large molecular libraries. 23 and (2) the identification of novel chemical entities to alter intracellular ion concentration by 1 inhibiting the Na + K + 2Clco-transporter (NKCC1) for the indication of autism. In a following section, 2
we demonstrate the application of BIOSEA for target identification, validated with both retrospective 3 data and prospective experiments that shed light on the polypharmacology of known drugs. 4
Consistently throughout these applications, BIOSEA revealed new relationships between molecules 5 and targets, which are difficult to detect even by a trained chemist's eye. 6
RESULTS

7
BIOSEA identifies molecules that reproduce a desired cellular phenotype 8 BIOSEA enables phenotypic screening without the need of information about the chemical structure 9 of the target or associated ligands ( Fig. 1a ). This capability was used in two drug discovery workflows 10 to find novel chemotypes that: (i) inhibit cell division and (ii) block NKCC1 mediated modulation of 11 intracellular ion concentration. In the first scenario, the cellular phenotype was characterized, and 12 both target and MoA of the proposed compounds were identified using cellular and biochemical 13 assays. In the second scenario, we applied BIOSEA for biological hit expansion with a NKCC1 14 cellular assay and compared its performance to standard methods that rely on chemical structure. 15
Phenotypic screening with BIOSEA: inhibition of cell division 16
As a reference set, we have selected six well-known natural products that perturb cell division in two 17 different ways: paclitaxel acts as a microtubule-stabilizing agent while the remaining compounds have 18 an inhibitory effect on tubulin polymerization. Virtual screening using these reference compounds and 19 a library of circa 365,000 compounds was performed to predict 20 biologically similar compounds 20 that would reproduce the phenotype of cell cycle arrest. 21
In a first validation step, using a cell cycle arrest screen in A549 cells, we could observe that 5 out 20 22
compounds were able to produce visible effects (rounding of cells) at a concentration of 5 µM which was indicative of a cytostatic behavior. The cytotoxic activity of the positive compounds (hereby 1 named CT1 to CT5) was verified in the same cell line, with most IC 50 values in the nanomolar range 2 (Table 1) . Additionally, it was confirmed that all 5 compounds completely depolymerized the 3 interphasic cellular microtubule network ( Fig. 2a ). To establish tubulin as the target that modulated 4 microtubule dynamics, the time-course of the assembly of tubulin was recorded in excess 5 concentration of the hit compounds ( Fig. 2b ). All compounds were found to inhibit tubulin 6 polymerization in vitro and in cells. Binding of active compounds in known tubulin depolymerizing 7 binding sites (i.e. colchicine, vinca, maytansine, and eribulin) was investigated using various 8 competition assays ( Fig. 2c , Supplementary Fig. 1 and Supplementary Fig. 2 ). CT5 was found to bind 9 to the eribulin biding site. The low solubility and weak activity of CT2 prevented any competition 10 assay. CT1, CT3 and CT4, were confirmed to bind to the colchicine site and a pharmacophore model 11 was proposed on the basis of colchicine-tubulin crystallographic information 24 to rationalize the 12 binding mode of these structurally diverse chemotypes ( Fig. 2d , Supplementary Information) . 13
Although the compounds do not share the same scaffold, the model showed a clear superimposition of 14 the di-and tri-methoxyphenyl moieties and good shape and chemical complementarity with the 15 reference compound, which indicates a similar binding pattern. 16
To deconvolute the information encoded in the HTSFP that leads to successful target-specific 17 compound predictions, we evaluated the individual contribution of every HTSFP assay to the global 18 biological similarity to the reference compounds. Thus, for each of the 5 hits, the top 10 HTSFP 19 components contributing most to the similarity were identified by a leave-one-out procedure 20 ( Supplementary Fig. 3 , Methods) and classified into biochemical or cell-based assays (Supporting 21 Table 1 ). Even though mutual information is a metric that is calculated based on the full range of the 22 HTSFP fingerprint, this approach provided the following observations on these highly informative 23 assays (HIA): a) there is no unique pattern for HIA that is common for all active compounds; 24 instead, each compound attributes its biological similarity to a different part of the fingerprint. For example, two compounds that were found to bind in the colchicine pocket, CT1 and CT4, do not have 1 any HIA in common ( Supplementary Fig. 3 ), and their biologically closest reference compounds are 2 also different (vincristine and vinblastine, respectively); b) no HIA exists for the phenotype of 3 interest (i.e. cell cycle arrest); only 2 assays measure unspecific cytotoxicity endpoints for Giardia 4 lamblia and Escherichia coli (Supplementary Table 1 ). The remaining HIA cover a diverse range of 5 biochemical and cell-based assays for targets such as the sentrin-specific protease 7, the sialic acid 6 acetylesterase or the vainilloid receptor 1, which are not associated to microtubule formation. It is 7 important to note that there is no tubulin-related assay in HTSFP; c) cell-based and biochemical 8 assays seem to contribute alike although most compounds resulted inactive in these HIA. While 9 compound activity in cell-based assays (Z-Score>2) may provide information on general cellular 10 perturbations (e.g. cytotoxicity, signaling pathways, etc.), inactivity throughout biochemical or 11 cellular assays (|Z-Score|<2) may bring information relevant for ruling out competing mechanisms 12 leading to a given phenotype. As an example, among its HIA the molecule CT2 has resulted inactive 13 for procaspases 3 and 7 -two biochemical assays-and inactive in a bacterial cell death screen in E-14
coli. 15
Hit expansion on NKCC1 16
The primary goal of hit expansion efforts following an HTS campaign is to leverage informative lead 17 molecules to rescue other active compounds that were neglected in the hit triage or missing in the 18 primary screening library. In a phenotypic screen, this approach is specially challenging due to the 19 diversity in chemical leads which may modulate several unknown targetsa context in which the 20 chemical similarity principle for hit expansion may not apply. 21
The Roche NKCC1 inhibitor program aimed at correcting imbalances in the GABA developmental 22 switch 25 , which controls the intracellular chloride concentration and shifts the functional role of 23 expression of two major ion co-transporters NKCC1 and KCC2, alterations in this mechanism 1 possibly result in CNS disorders including epilepsy, autism spectrum disorder, schizophrenia and 2 effects of traumatic brain injury 26 . The goal of the project was to identify NKCC1 inhibitors with high 3 selectivity over peripherally expressed NKCCs and largely improved brain exposure compared to 4 available compounds from the loop diuretic class such as bumetanide. 5
To this end, a primary screen of more than 1.2 million compounds within the Roche library was 6 conducted. The screen had a low hit rate of 0.06% confirmed active compounds covering several 7 compound classes. A standard approach that relies on the generation of 3D shapes and surface charge 8 models (ROCS 27 ) was applied and 430 compounds pharmacophorically similar to selected active 9 compounds were submitted for profiling. This procedure resulted in a single novel hit with an affinity 10 of 9 µM. For biological hit expansion using BIOSEA, 12 confirmed hits with IC 50 in the low 11 micromolar to submicromolar range for NKCC1 were used as the reference set for the virtual 12 screening of the Roche 1.2-million-compound library. Compounds were sorted by biological 13 similarity (i.e. e-value) to the reference set and the top 44 compounds were tested for their NKCC1 14 activity in the profiling cellular assay. This resulted in the identification of three molecules with an 15 IC 50 below 30 µM ( Fig. 3 ). Not only was there a significant improvement in the hit rate by using 16 BIOSEA compared to traditional approaches based on 2D or 3D chemical information 28 , but, in 17 addition, two of these molecules provided novel chemotypes ( Fig. 3 ) useful for further optimization 18 efforts. The remaining hit had a very similar chemotype to the reference compounds, which served as 19 a control result given that BIOSEA operates independently from chemical structure. 20
BIOSEA can identify new targets for old compounds 21
Using BIOSEA, we investigated the polypharmacology of known drugs and evaluated the method's 22 potential to identify novel targets following the procedure described in Fig. 1b . 23
Our efforts were focused on 711 FDA-approved, withdrawn or experimental drugs. BIOSEA was 1 used to assess their possible associations with public domain targets from the ChEMBL database 29 . 2
Each molecule was assigned a maximum of 10 predicted targets above a minimum threshold of e-3 value, building a pool of 1,124 predictions, out of which 407 could be either experimentally validated 4 or found in the literature. None of the reported target-compound associations were part of the training 5 set and none of the attributed targets were part of the HTS fingerprint. Noteworthy, we predicted and 6 experimentally confirmed 5 novel and unreported compound-target associations for drugs: pimozide, 7 fluspirilene, reserpine, and nimodipine ( Table 2) Additionally, BIOSEA was able to broadly capture the pharmacological profile of other antipsychotics (i.e. prochlorperazine and perphenazine), for which it could detect four or more 1 annotations (Supplementary Data Set 1). The efficacy of those drugs in the treatment of schizophrenia 2 and other mental illnesses has been previously linked to their ability to modulate multiple targets 31 3 predominantly receptors subtypes and transporters of neurotransmitters (adrenaline, dopamine and 4 serotonin). (ii) Target identification provides a rationale for side effects: In addition to NET, 5 fluspirilene activity on the adrenergic α 2B receptor (ADRA2B, IC 50 = 95 nM), a target related to 6 vasoconstriction and blood pressure regulation 32 was predicted and experimentally confirmed. 7
Reducing blood pressure in patients with hypertension is documented 33 as a side effect of fluspirilene, 8
to which this ADRA2B activity could contribute. (iii) Compound repurposing opportunity: we 9 predicted and experimentally confirmed the glucocorticoid receptor (GR) activity (IC 50 = 640 nM) for 10 the neuroprotective agent nimodipine. Established as a selective L-type voltage-dependent calcium 11 channel antagonist, nimodipine is often used in the treatment of subarachnoid hemorrhage 34 . Animal 12 studies have shown that nimodipine is able to improve cognitive performance 35 , block memory 13 destabilization and prevent memory reconsolidation 36 . On the other hand, it is well established that 14 glucocorticoids influence cognitive performance and have impairing effects on memory function and 15 consolidation 37 . Post-traumatic stress disorder (PTSD) is reported to be associated with 16 increased glucocorticoid receptor sensitivity 38 . Our finding, therefore, suggests opportunities in using 17 nimodipine in connection with psychological disorders associated with GR such as PTSD, although 18 this possibility should be studied in more detail. 19
Taken together, 31% of validated target-compound relationships could be either positively confirmed, 20 or putatively confirmed when a positive result was found in the literature for an orthologue target or 21 convincing evidence of the relationship has been reported but is not quantified (Fig. 4a ). Among 22 compounds with validated predictions, 70 out of 193 were successfully assigned to at least one 23 confirmed or putative target using BIOSEA. The same target identification benchmarking protocol 24 was repeated using an in-house version of SEA 12 , which is based on chemical fingerprints (Supplementary Information). Only 4% of BIOSEA's total predictions were shared with SEA, which 1 hints at a high degree of complementarity between both methodologies. However, while 2 approximately 80% of the positive results from SEA can be explained by the high structural similarity 3 between the query compounds and the training set, only 32% of BIOSEA's confirmed predictions 4 could have been inferred in this way (Fig. 4c) . The remaining predictions are not structurally obvious 5
and suggest that HTSFP encode information that goes beyond a pure pharmacophore description and 6 captures more general biological phenomena (see examples Fig. 4d) . 7
Positive predictions from BIOSEA span both functional assays (63%) and binding assays (37%) (Fig.  8   4b) . These percentages are in agreement with the biases in our database regarding the ratio of binding 9 vs. functional annotations, indicating that the method performs equally well independently to the type 10 of readout by which these predictions are confirmed. This result is consistent with previous 11 observations making use of HTSFP which contain both cell-based and biochemical HTS assays 16, 22 . 12
An interesting example among the literature-confirmed predictions is the inhibitory activity of 13 amoxicillin (IC 50 = 3.47 µM) on carbonic anhydrase XII 39 . This prediction illustrates the ability of 14 BIOSEA to capture bioisosterism, since it was mostly based in the biologically similarity to 15 compounds in the training set such as 4-sulfamoylbenzoic acid, sulpiride or indapamide, all of them 16 sulfonamides. Though structurally unrelated to amoxicillin, all these compounds have in common a 17 chemical group that is able to interact with the zinc atom in the enzyme's active site (carboxylate or 18 sulfonamide moieties respectively). 19
DISCUSSION 20
Our results demonstrate that BIOSEA is able to classify compounds according to their biological 21 signature from HTS data. Applied to phenotypic screening, this approach can identify compounds that 22 are likely to produce a desired phenotype as captured in the biological signature of several reference 23 compounds. We show that this procedure is possible even in the absence of information on the particular target(s) responsible for the compounds' mode of action. The results for tubulin and 1 NKCC1 show that the applicability domain of the method goes beyond the target, target families and 2 phenotypes that have been historically screened and represented in the HTSFP. HTSFP are unique in 3 the fact that they capture information on compound inactivity as well as compound activity, both 4 equally relevant to the mutual information between fingerprints. While the desired phenotype, cell 5 cycle arrest in this case, can be triggered by multiple mechanisms of action, interestingly, our hits 6 bind to the same target and follow the mechanism of action of their reference compounds. This 7 suggests that HTSFP are able to encode target-specific information (i.e. tubulin binding). The 8 opportunity of using this approach for finding compounds that can reverse a particular disease 9 phenotype remains an exciting avenue for further exploration. 10
In addition, the NKCC1 results suggest that the success of the screening effort can be evaluated not 11 only in terms of hit enrichment but also in the novelty and variety of active chemical structures. For 12 this reason, BIOSEA becomes an effective tool for building screening libraries for drug discovery 13 programs, even if the target is novel and challenging, as is the case for NKCC1. 14 In target identification, our method can be used to discriminate among different drug targets by the 15 similarity in the biological signatures of their corresponding ligands. Using our protocol we have 16 explored the pharmacological profile of known drugs. Despite the fact that most of them have been 17 optimized for selectivity, BIOSEA was able to accurately predict drug polypharmacology in many G-18 protein coupled receptors and a wide variety of enzyme classes, consistent with the annotation biases 19 in public 40 and industrial databases 41 towards specific target families. In particular, we demonstrate 20 the applicability of our method for drug repurposing and rationalization of drug side effects. 21
Moreover, the majority of the confirmed predictions cannot be rooted in obvious chemical similarity 22
to reference compounds. This shows that BIOSEA provides complementary information to traditional 23 computational methodologies.
Despite its advantages, the approach has some inherent limitations, such as the availability of the HTS 1 signature for a particular compound and the existence of suitable reference compounds for a given 2 target or phenotype of interest. Additionally, for target identification, BIOSEA restricts its findings to 3 the target domain that is known and has several annotated ligands. Nonetheless, with its performance 4 validated in these in-house drug discovery and target identification scenarios, BIOSEA, offers a 5 complementary and alternative source for hypothesis generation by capitalizing on already existing 6 information resources. 7
Trained solely on public data, our innovative approach is within the reach of both academic and 8 industrial research groups. We invite the scientific community at large to contribute and explore this 9 technology by providing the computer code and the HTSFP public data set for download 10 (https://github.com/accsc/BIOSEA), in the hope that it will foster present and future drug discovery 
METHODS
19
Biological fingerprints from HTS: HTS fingerprints (HTSFP) were built using screening data from 20
PubChem, consisting of 95 primary screening assays over a library of 365,231 molecules in a similar 21 way to what was described in earlier works 21 (Supplementary Information). HTS results were 22 normalized using the average response and the standard deviation to transform all the readouts to Z-23 Biosimilarity metric. A derived version of the mutual information (I) was introduced to estimate the 1 similarity between two biological fingerprints Z NMI : 2
where X and Y are the HTSFP reduced to the assays in common for compounds x and y; I(X;Y) is the 4 estimated mutual information using the Kraskov entropy estimator from k-nearest neighbor 5 distances 42 ; H(X) and H(Y) are the Shannon entropies 43 ; and σ(n) was introduced to correct for the 6 dependency in fingerprint-size n, parametrized based on a background distribution of random 7 fingerprint comparisons (a more detailed procedure can be found in Supplementary Information). An 8 optimal value of k = 10 was selected for the calculation of I(X;Y) based on previous parameter 9 analysis (data not shown) and as trade-off between minimal fingerprint length required and a reliable 10 Z NMI calculation. 11
BIOSEA.
A statistical method to classify compounds into target classes using biological signatures 12 from HTS was developed, inspired by the BLAST 23 and SEA 11 algorithms. BIOSEA provides an e-13 value that represents the likelihood of a compound to be related by chance to a given compounds set, 14 by aggregating the biological similarities (Z NMI ) between the compound and the members of the set, 15 and comparing the aggregated value to a random distribution of sums. To build the background 16 distribution, random lists of HTSFP were generated with sizes in the range s = 1 to s = 100. The 17 aggregated biological similarity between every two pairs of lists of compounds with sizes 1 and m 18 respectively was calculated. The average and standard deviation of the random sums of Z NMI per 19 number of comparisons (l x m) were calculated and fitted to two power-law equations (Supplementary 20 Table 2 ). Aggregated biological similarities were transformed to Z-Scores (Z AG ) and plotted in a 21 histogram that conformed to an Extreme Value Distribution (EVD), whose location, scale and shape 22 parameters were estimated ( Supplementary Table 3 ). This distribution was used as a background for probability calculation and its conversion to an expectation value (e-value) that evaluates the 1 significance of the relationships between given sets of fingerprints. The choice of Z NMI threshold 2 between fingerprints selects which compounds are relevant for the aggregated biological similarity 3 and has an effect on the Z AG distribution. Z NMI values of 0.5 and 4.5 in increments of 0.1 were tested 4 and minimal (Z NMI = 2.6) and optimal values (Z NMI = 4.0) were obtained. More detailed information 5 can be found on Supplementary Information. 6
Individual assay contributions to the aggregated similarity. For each compound with tubulin 7 depolymerizing activity, we carried out a leave-one-out procedure in which the aggregated biological 8 similarity of an individual compound to the reference compounds (Z AG ) was calculated after removing 9 one assay at a time. The difference in Z AG between using the complete fingerprint and the version with 10 a removed component was computed and used to rank the assays. The first 10 assays with the highest 11 similarity difference were selected for analysis. 12
Target identification database. For the training of BIOSEA, a database of 265 targets and their 13 known ligands was built using dose-response annotations (IC 50 , EC 50 , AC 50 , K i , K d , Potency) from 14
ChEMBLdb release 20 29 . Molecules with at least one measurement below 5 µM and none higher than 15 15 µM were considered active. Only targets with at least 10 annotated ligands were included. 16
Frequent binders (actives in more than 5 assays) were removed from the datasets. A total of 21,157 17 annotations for 19,808 molecules were collected as the training set for target identification 18
(Supplementary Data Set 2). 19
Predictions for target identification. 711 known drugs were extracted from DrugBank 44 and 20
ChEMBLdb release 20. Predictions were carried out by BIOSEA trained on the target identification 21 database. The compound biosimilarity threshold was defined as Z NMI >2.6. The threshold for 22 compound-target predictions was e-value > 2.72x10 -5 (equivalent to Z AG > 8.0) resulting in a total 23 pool of 1,124 predictions. The 164 predictions for which the target is represented in the HTSFP were eliminated from the statistics. A total of 407 remaining predictions were literature or experimentally 1 verified. ChEMBLdb release 20, DrugBank and Thomsons Reuters Integrity databases were scanned 2 for activity confirmation. PubMed and EMBASE databases were inspected with the text mining 3 Linguamatics I2E tool for additional evidence. Predictions were confirmed as active by a retrieved 4 dose-response value below a threshold of 20 µM, or they were supported by literature annotations 5 without a numeric readout. A subset of 169 unreported testable hypotheses (accessible compounds 6 and available assays, see Supplementary Data Set 1) was extracted for experimental evaluation. 7
Analysis of the 2D compound similarity was performed using ECFP4 fingerprints generated by 8 Pipeline Pilot 9.2 with a Tanimoto coefficient threshold of 0.8. 3D compound similarity was 9 calculated using a ROCS-clone 27,45 based on Gaussian shape similarity and a Tanimoto combo 10 threshold of 1.5. 11 NKCC1 assay. HEK293 cells conditionally expressing NKCC1 were grown under doxycycline 12 selection. Cell cultures were maintained at 37 °C in the presence of 5% CO 2 and 85% of humidity. A 13 volume of 50 μl containing 25,000 cells was plated on poly-D-lysine dishes and induced for 24h. 14 Cells were washed and incubated at 37°C in the presence of 5% CO 2 for 50 min with a hypotonic 15 buffer. The supernatant from the cells was removed to a final 21 μl volume and 25 μl of compound 16 solution diluted in rubidium containing buffer was added. After 10 min incubation, cells were washed 17 with a hypotonic buffer and 21 μl of 2% tergitol NP-40 was added per well. Plates were sealed and 18 stored overnight at room temperature. Finally, 30 μl of supernatant for each well were diluted in 170 19 μl of water and the rubidium content was measured using an atomic absorption spectrophotometer at 20 780 nm (Aurora Biomed, ICR 12000). Bumetanide was used as the reference compound for 21 calculation of percentage of inhibition for each compound. Morphology and cytotoxicity cellular assay. Cytotoxicity evaluation was performed on A549 23 human lung carcinoma cells (ATCC), employing a modified MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-24 diphenyltetrazolium bromide) assay 46 . Indirect immunofluorescence was performed in A549 cells, as previously described 47 . An absorbance spectrum in methanol was made for each compound in a 1 spectrophotometer Evolution 201 (Thermo Scientific) in order to identify the absorbance maxima. to search in the HTSFP PubChem collection with a Z NMI threshold of 4.0. The resulting 1,559 20 molecules were structurally clustered using the ECFP4 fingerprints generated by Pipeline Pilot 9.2 21 and sorted according to Z AG . Known tubulin inhibitors and their chemically similar cluster members 22
were removed and first 20 compounds were selected for confirmation. compounds that are active in a given target. Target sets are ranked according to Z AG and the top 10 7
targets are defined as target predictions for the query compound. compounds provided starting points for hit expansion within a 2-million-compound virtual library. Hit 2 expansion was carried out by three complementary approaches: chemical, pharmacophore and 3 biological similarity which produced in total ~500 compounds to be tested in a confirmatory dose-4 response assay, resulting in 4 leads with IC50<30 µM. (Bottom) Chemical similarity (Tanimoto 5 distance of ECFP4 fingerprints) vs. biological similarity (represented by ). The regions relevant for 6
chemical and biological expansion are highlighted in red and green respectively. Green and orange 7 dots represent NKCC1 tested biological and pharmacophore similarity predictions. 
